|
1
|
DeSantis C, Naishadham D and Jemal A:
Cancer statistics for African Americans, 2013. CA Cancer J Clin.
63:151–166. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayes JH and Barry MJ: Screening for
prostate cancer with the prostate-specific antigen test: A review
of current evidence. JAMA. 311:1143–1149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ,
Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, et al: A serum microRNA
classifier for early detection of hepatocellular carcinoma: A
multicentre, retrospective, longitudinal biomarker identification
study with a nested case-control study. Lancet Oncol. 16:804–815.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y,
Mao XH, Wu C, Yang SM, Zeng H, Zou QM and Guo G: MicroRNA-25
promotes gastric cancer migration, invasion and proliferation by
directly targeting transducer of ERBB2, 1 and correlates with poor
survival. Oncogene. 34:2556–2565. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sapre N, Macintyre G, Clarkson M, Naeem H,
Cmero M, Kowalczyk A, Anderson PD, Costello AJ, Corcoran NM and
Hovens CM: A urinary microRNA signature can predict the presence of
bladder urothelial carcinoma in patients undergoing surveillance.
Br J Cancer. 114:454–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharova E, Grassi A, Marcer A, Ruggero K,
Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M
and Ciminale V: A circulating miRNA assay as a first-line test for
prostate cancer screening. Br J Cancer. 114:1362–1366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin C, Fang C, Weng H, Yuan C and Wang F:
Circulating microRNAs as novel biomarkers in the diagnosis of
prostate cancer: A systematic review and meta-analysis. Int Urol
Nephrol. 48:1087–1095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Walter BA, Valera VA, Pinto PA and Merino
MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer.
4:350–357. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fletcher CE, Dart DA, Sita-Lumsden A,
Cheng H, Rennie PS and Bevan CL: Androgen-regulated processing of
the oncomir miR-27a, which targets prohibitin in prostate cancer.
Hum Mol Genet. 21:3112–3127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma Y, Yu S, Zhao W, Lu Z and Chen J:
miR-27a regulates the growth, colony formation and migration of
pancreatic cancer cells by targeting Sprouty2. Cancer Lett.
298:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng H, Wang X, Zhang P, Sun T, Ren X and
Xia Z: miR-27a promotes cell proliferation and metastasis in renal
cell carcinoma. Int J Clin Exp Pathol. 8:2259–2266. 2015.PubMed/NCBI
|
|
14
|
Salah Z, Arafeh R, Maximov V, Galasso M,
Khawaled S, Abou-Sharieha S, Volinia S, Jones KB, Croce CM and
Aqeilan RI: miR-27a and miR-27a* contribute to metastatic
properties of osteosarcoma cells. Oncotarget. 6:4920–4935. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao N, Sun H, Sun B, Zhu D, Zhao X, Wang
Y, Gu Q, Dong X, Liu F, Zhang Y and Li X: miR-27a-3p suppresses
tumor metastasis and VM by down-regulating VE-cadherin expression
and inhibiting EMT: An essential role for Twist-1 in HCC. Sci Rep.
6:230912016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bostwick DG: Staging prostate cancer-1997:
Current methods and limitations. Eur Urol. 32 Suppl 3:S2–S14.
1997.
|
|
17
|
Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo
X, Mao XH, Zou QM, Yu PW, Zuo QF, et al: Plasma microRNAs, miR-223,
miR-21 and miR-218, as novel potential biomarkers for gastric
cancer detection. PLoS One. 7:e416292012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Barros Pita W, Leite FC, de Souza
Liberal AT, Pereira LF, Carazzolle MF, Pereira GA and de Morais MA
Jr: A new set of reference genes for RT-qPCR assays in the yeast
Dekkera bruxellensis. Can J Microbiol. 58:1362–1367. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel R, Gao M, Ahmad I, Fleming J, Singh
LB, Rai TS, McKie AB, Seywright M, Barnetson RJ, Edwards J, et al:
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer
progression. J Clin Invest. 123:1157–1175. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hacohen N, Kramer S, Sutherland D, Hiromi
Y and Krasnow MA: sprouty encodes a novel antagonist of FGF
signaling that patterns apical branching of the Drosophila airways.
Cell. 92:253–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McKie AB, Douglas DA, Olijslagers S,
Graham J, Omar MM, Heer R, Gnanapragasam VJ, Robson CN and Leung
HY: Epigenetic inactivation of the human sprouty2 (hSPRY2)
homologue in prostate cancer. Oncogene. 24:2166–2174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Liang S, Xiao S, Lin Q, Chen X, Wu
Y and Fu J: MicroRNA-27b inhibits Spry2 expression and promotes
cell invasion in glioma U251 cells. Oncol Lett. 9:1393–1397. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao B, Wang Y, Li W, Baker M, Guo J,
Corbet K, Tsalik EL, Li QJ, Palmer SM, Woods CW, et al: Plasma
microRNA signature as a non-invasive biomarker for acute
graft-versus-host disease. Blood. 122:3365–3375. 2013. View Article : Google Scholar : PubMed/NCBI
|
